Volociximab

Embed this Topic
Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.
Read article at Wikipedia

Also known as:

  • M200

Facts from the Community

From the BioVenturist base

Indication or disease:

Disease Phase of development
View entire collection »

Technology involved:

Developed by:

Stage of development:

top ↑

We can tell you that Volociximab is a…

If you know more about Volociximab, you can add more facts here »

You can help improve this topic by adding more facts here

Edit this topic
Edit and Show details

Add or delete facts, download data in JSON or RDF formats, and explore topic metadata.

Freebase Logo
What is Freebase?

Freebase is a huge collection of facts, built by people like you. Freebase connects facts in ways other sites can't, giving you new ways to explore millions of subjects.
You can help improve it!

Freebase Attribution

Freebase data is free for use under the CC-BY license.

The original description for Volociximab was automatically generated from Wikipedia.org licensed under the GNU Free Documentation License.
[1]
Learn more about Freebase licensing and attribution